1,017
Participants
Start Date
September 1, 2014
Primary Completion Date
May 25, 2015
Study Completion Date
June 15, 2015
Umeclidinium
Umeclidinium 62.5 mcg once daily in the morning via nDPI
Umeclidinium matching placebo
Umeclidinium matching placebo once daily in the morning via nDPI
Tiotropium
Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
Tiotropium matching placebo
Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
GSK Investigational Site, Boksburg
GSK Investigational Site, Vrededorp
GSK Investigational Site, København NV
GSK Investigational Site, Hvidovre
GSK Investigational Site, Durban
GSK Investigational Site, Port Elizabeth
GSK Investigational Site, Korsten
GSK Investigational Site, Somerset West
GSK Investigational Site, Bellville
GSK Investigational Site, Mowbray
GSK Investigational Site, Aarhus C
GSK Investigational Site, Welkom
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Milan
GSK Investigational Site, Spartanburg
GSK Investigational Site, Poltava
GSK Investigational Site, Negrar
GSK Investigational Site, Tours
GSK Investigational Site, Bletterans
GSK Investigational Site, Nantes
GSK Investigational Site, Riccione (RN)
GSK Investigational Site, Dnipropetrovsk
GSK Investigational Site, Kryvyi Rig
GSK Investigational Site, Pisa
GSK Investigational Site, Vieux-Condé
GSK Investigational Site, Torrette (AN)
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Kharkiv
GSK Investigational Site, Kharkiv
GSK Investigational Site, Rodgau
GSK Investigational Site, Neu-Isenburg
GSK Investigational Site, Aschaffenburg
GSK Investigational Site, Wiesbaden
GSK Investigational Site, Zaporizhzhia
GSK Investigational Site, Toulon
GSK Investigational Site, Ploieşti
GSK Investigational Site, Moscow
GSK Investigational Site, Arkhangelsk
GSK Investigational Site, Arkhangelsk
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Sestroretsk
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Timișoara
GSK Investigational Site, Deva
GSK Investigational Site, Sochi
GSK Investigational Site, Stavropol
GSK Investigational Site, Izhevsk
GSK Investigational Site, Ufa
GSK Investigational Site, Codlea
GSK Investigational Site, Vladimir
GSK Investigational Site, Bacau
GSK Investigational Site, Comuna Alexandru Cel Bun
GSK Investigational Site, Focşani
GSK Investigational Site, Novosibirsk
GSK Investigational Site, Tomsk
GSK Investigational Site, Kemerovo
GSK Investigational Site, Irkutsk
GSK Investigational Site, Galati
GSK Investigational Site, Brăila
GSK Investigational Site, Valparaíso
GSK Investigational Site, Talcahuano
GSK Investigational Site, Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Winnipeg
GSK Investigational Site, St. John's
GSK Investigational Site, Truro
GSK Investigational Site, Greater Sudbury
GSK Investigational Site, Toronto
GSK Investigational Site, Toronto
GSK Investigational Site, Montreal
GSK Investigational Site, Québec
GSK Investigational Site, Québec
GSK Investigational Site, Saint-Charles-Borromée
GSK Investigational Site, Sherbrooke
GSK Investigational Site, Odense
GSK Investigational Site, Dresden
GSK Investigational Site, Teuchern
GSK Investigational Site, Schmölln
GSK Investigational Site, Bucharest
GSK Investigational Site, Barnaul
GSK Investigational Site, Moscow
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Lynnwood Ridge, Pretoria
GSK Investigational Site, Bucheon-Si, Gyeonggi-Do
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Wonju-si, Gangwon-do
GSK Investigational Site, Kiev
GSK Investigational Site, Kyiv
Lead Sponsor
GlaxoSmithKline
INDUSTRY